Clinical trial • Phase I • Endocrinology
GUB-UCN2 for Type 2 diabetes | Obesity
Phase I trial of GUB-UCN2 for Type 2 diabetes | Obesity. 220 participants.
Overview
- Trial Therapeutic Area
- Endocrinology
- Trial Disease
- Type 2 diabetes | Obesity
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 25-02-2026
- First CTIS Authorization Date
- 11-05-2026
Trial design
Phase I trial across 1 site in Germany.
- Target Sample Size
- 220
Eligibility
Recruits 220 Vulnerable populations selected; no details on consent or assent handling provided..
- Vulnerable Population
- Vulnerable populations selected; no details on consent or assent handling provided.
Recruitment
- Planned Sample Size
- 220
- Recruitment Window Months
- 29
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 220
Germany
- Earliest CTIS Part Ii Submission Date
- 07-05-2026
- Latest Decision Or Authorization Date
- 11-05-2026
- Processing Time Days
- 4
- Number Of Sites
- 1
- Number Of Participants
- 220
Sites
- Site Name
- PROFIL Institut fuer Stoffwechselforschung GmbH
- Contact Person Name
- Grit Andersen
- Contact Person Email
- grit.andersen@profil.com
Sponsor
Primary sponsor
- Full Name
- Gubra A/S
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Denmark
Investigational products
- Investigational Product Name
- GUB-UCN2
- First In Human
- Yes
Related trials
Other published trials that may interest you.